NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Search Tool Menu
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Menu
Close Button
Leadership


Vincent Fert
Executive Vice President, Immuno-Oncology and EU Strategic Initiatives

Vincent Fert has extensive diagnostic leadership experience, most recently serving as the Founder, Chairman and Chief Executive Officer of HalioDx, an immuno-oncology diagnostics company acquired by Veracyte in August 2021. A serial entrepreneur, Mr. Fert was formerly a member of the board and Chief Executive Officer of Qiagen Marseille and Vice President, Personalized Healthcare Care Program Lead for Qiagen N.V. In 1999, he founded Ipsogen, which became a leader in the molecular diagnosis of leukemia and an Alternext-listed company, before being acquired by Qiagen in 2011. Mr. Fert was formerly an R&D lead at Beckman Coulter and Immunotech. He holds a degree in Immunology from Aix-Marseille University.